CD8A and neoplasm: These trials stem from our previous work showing that FAK knockout or the FAK kinase inhibitor VS-4718 can drive complete CD8 T-cell dependent regression of established SCC tumors through shifting the balance of CD8 T-cells: Regulatory T-cells (Tregs) in favor of tumor clearance (Serrels et al., 2015), and that of others showing that VS-4718 can drive reprogramming of the immuno-suppressive pancreatic TME, including a reduction in Tregs, CD206+ macrophages, myeloid-derived suppressor cells (MDSCs), and stromal fibroblasts.